Clinical Trials Logo

Digestive System Diseases clinical trials

View clinical trials related to Digestive System Diseases.

Filter by:

NCT ID: NCT05708963 Completed - Clinical trials for Cardiovascular Diseases

The U.K. Embryologist Fatigue Study

FUSE-UK
Start date: January 16, 2023
Phase:
Study type: Observational

The purpose of the study is to determine physical and mental health issues of U.K. embryologists related to their occupational characteristics, and how workplace fatigue and burnout may affect their quality of life, cynicism, interactions with patients, attention to detail, and lead to human error, the cause of the most severe IVF incidents that often make headlines and result in costly litigation. It will also correlate how the current manual workflows contribute to these health issues, and what measures can be taken to improve both working conditions and embryologists' health, and, therefore, improve patient care.

NCT ID: NCT05682105 Active, not recruiting - Clinical trials for Artificial Intelligence

Detection of Jaundice From Ocular Images Via Deep Learning

Start date: December 1, 2018
Phase:
Study type: Observational

Our study presents a detection model predicting a diagnosis of jaundice (clinical jaundice and occult jaundice) trained on prospective cohort data from slit-lamp photos and smartphone photos, demonstrating the model's validity and assisting clinical workers in identifying patient underlying hepatobiliary diseases.

NCT ID: NCT05668104 Completed - Healthy Subjects Clinical Trials

Jing Si Herbal Tea for Long-Coronavirus Disease(COVID) Gut-brain Interaction

Start date: January 1, 2023
Phase: N/A
Study type: Interventional

Dyspepsia refers to chronic or recurrent upper gastrointestinal symptoms. According to the Rome IV criteria, functional dyspepsia (FD) symptoms included meal related fullness, early satiation, epigastric pain or burning which are unexpl ained after routine investigation. FD causes substantial psychophysical burden because of its unknown etiology and high prevalence. Although FD is currently associated with local inflammation of the gastrointestinal tract and microbiota alteration, current available treatments for FD are of limited effectiveness. In view of this, many studies have applied Chinese herbal medicine in FD and achieved some therapeutic benefit. The Jing Si Herbal Tea Liquid Packet composed of eight native Taiwanese herbs (wormwo od, hickory grass, Ophiopogon japonicus, houttuynia cordata, platycodon,licorice, perilla leaves, chrysanthemum) has obtained a special export license from the Ministry of Health and Welfare. The Jing Si Herbal Tea Liquid Packet also has been registered i n clinical trials as a complementary treatment for Coronavirus disease 2019(COVID-19). The preliminary data demonstrated that the Jing Si Herbal Tea Liquid Packet may improve gastrointestinal symptoms and anxiety in patients with COVID-19. Therefore,this study aims to investigate the impact of the Jing Si Herbal Tea Liquid Packet on psychophysical burden and metabolites of microbiota in patients with FD through a double blind randomized manner.

NCT ID: NCT05664113 Not yet recruiting - Clinical trials for Gastro-Intestinal Disorder

Feasibility, Safety, and Potential Efficacy of Fecal Microbiota Transplantation (FMT) for Gastrointestinal Dysfunction in Children Following Hematopoietic Cell Transplant (HCT).

Start date: June 2024
Phase: Phase 1
Study type: Interventional

The study participant is being asked to take part in this clinical trial, a type of research study, because the participant has Gastrointestinal (GI) symptoms following a Hematopoietic Cell Transplant (HCT). Primary Objective - To determine the safety and feasibility of FMT for treating a GvHD of the gut following HCT. - To determine the safety and feasibility of FMT for treating HCT induced gut dysfunction. Secondary Objectives - To assess the potential efficacy of FMT for treating a GvHD of the gut following HCT. - To assess the potential efficacy of FMT for treating HCT induced gut dysfunction.

NCT ID: NCT05640401 Recruiting - Clinical trials for Gastrointestinal Diseases

Holographic Screens as a Replacement of Monitors During GI Endoscopies

Start date: November 21, 2022
Phase: N/A
Study type: Interventional

Nowadays, the application and development of spatial technologies have shown an increased interest in different fields of medicine, especially in procedural specialties. Many studies have shown the utility of augmented and virtual reality; however, studies evaluating mixed reality are scarce. In gastroenterology, some proposed advantages of MR are the 3D space guidance, its increased situational awareness, remote assistance, and the reduction of surgical monitors in the units. Based on this, the researchers proposed a multicenter trial to assess the added value of MR through a holographic device during gastroenterology endoscopic procedures.

NCT ID: NCT05636657 Not yet recruiting - Crohn Disease Clinical Trials

Comparative Study of Intestinal Color Ultrasound and Capsule Endoscopy in Monitoring Crohn's Disease

Start date: November 30, 2022
Phase:
Study type: Observational

The disease activity index under intestinal color ultrasound was evaluated by SUS-CD, and the disease activity index under capsule endoscopy was evaluated by CECDAI. All subjects underwent intestinal color ultrasound and capsule endoscopy at baseline and at the third month of treatment. To compare the correlation between SUS-CD and CECDAI before and after treatment, and to compare the role of intestinal color ultrasound and capsule endoscopy in monitoring Crohn's disease in small intestine.

NCT ID: NCT05636358 Active, not recruiting - Clinical trials for Irritable Bowel Syndrome

Hypnotherapy Through Self-exercises in Children With Functional Abdominal Pain in Primary Care

ZelfHy
Start date: March 5, 2021
Phase: N/A
Study type: Interventional

The goal of this randomised controlled trial is to study the (cost-)effectiveness of home-based hypnotherapy by self-exercises in children with functional abdominal pain (FAP) or irritable bowel syndrome (IBS) in primary care. The main questions it aims to answer are: - What is the effect of home-based hypnotherapy by self-exercises on adequate relief of abdominal pain and discomfort in addition to care as usual of general practitioners (GPs), compared to care as usual of GPs alone in children with FAP or IBS? - What is the effect of home-based hypnotherapy by self-exercises in addition to care as usual by GPs compared to care as usual of GPs alone in children with FAP or IBS on: - Frequency and intensity of abdominal pain and discomfort - Pain severity - Daily functioning and impact - Anxiety and depression - Pain beliefs - Sleep disturbances - School absence - Use of health care services, including GP visits and referrals to secondary care - Costs (healthcare and societal perspective) Participants in the intervention group will receive home-based hypnotherapy 5 times a week for approximately 15-20 minutes a day during 3 months in addition to care as usual by their GP according to the Dutch society of GPs' guideline for children with abdominal pain. Participants in the control group will receive care as usual by their GP according to the Dutch society of GPs' guideline for children with abdominal pain.

NCT ID: NCT05627882 Recruiting - Clinical trials for Gastro-Intestinal Disorder

Evaluation of the Impact of a Forward Viewing Scope at Time of ERCP

Start date: October 14, 2022
Phase:
Study type: Observational

This study will be a prospective, tandem-designed study to determine the proportion of clinically significant missed lesions when using a side- or oblique-viewing endoscope as compared to the standard forward-viewing endoscope. Utilizing standard endoscopy protocols in current practice at Brigham and Women's Hospital, consecutive adult patients undergoing ERCP for traditional reasons will undergo back-to-back tandem EGD and ERCP examinations. This process entails an EGD performed by an attending gastroenterologist first. Next, a second blinded attending gastroenterologist will perform ERCP immediately after index EGD. Both endoscopists will note any clinically significant findings, independent of the other providers procedural findings. Clinically significant findings defined as endoscopic findings that alter patient management (i.e., esophageal varices, peptic ulcer disease, hemorrhage, mass, etc.) during EGD and ERCP will be recorded. As previously stated, some institutions already routinely perform EGD with every ERCP.

NCT ID: NCT05612347 Recruiting - Colorectal Cancer Clinical Trials

Colonoscopy vs Stool Testing for Older Adults With Colon Polyps

COOP
Start date: June 14, 2023
Phase: N/A
Study type: Interventional

This is a multi-site comparative effectiveness randomized controlled trial (RCT) comparing annual fecal immunochemical testing (FIT) and colonoscopy for post-polypectomy surveillance among adults aged 65-82 with a history of colorectal polyps who are due for surveillance colonoscopy.

NCT ID: NCT05605405 Not yet recruiting - Clinical trials for Functional Gastrointestinal Disorders

Prevalence and Associated Factors of Functional Gastrointestinal Disorders Among Children

Start date: December 2022
Phase:
Study type: Observational

The definition of Functional Gastrointestinal Disorders (FGIDs) has changed over time from the absence of organic disease to a stress-related or psychiatric disorder to a motility disorder, and with Rome III, to a disorder of GI functioning, then Rome iv in 2016 defined FGIDs as : disorders of gut-brain interaction. It is a group of disorders classified by GI symptoms related to any combination of the following: motility disturbance, visceral hypersensitivity,altered mucosal and immune function, altered gut microbiota, and altered central nervous system (CNS) processing. FGIDs are observed in infants and young children worldwide with variable frequency related studies done in variable places around the worled show the following results : the prevalence of FGIDs in Chinese infants and young children is 27.3%.and 40 % in south american infants and 30 % of african infants and 35.1 % of infants presented to tertiary care hospital in Istunbul.Turkey.